- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For First Quarter 2026 | 49 | GlobeNewswire (Europe) | A difficult quarter in a year of necessary change
Q1 2026 KEY INDICATORSTotal revenue amounted to 71.7 MSEK (85.1)EBITDA equalled -6.6 MSEK (12.8)Operating profit (EBIT) was -17.8 MSEK (2.1)Profit after... ► Artikel lesen | |
| MAGLE CHEMOSWED Aktie jetzt für 0€ handeln | |||||
| 26.05. | Magle Chemoswed Holding AB: Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ) | 215 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), today, on 26 May 2026, held an Extraordinary General Meeting (the "EGM") at the Company's premises at Agneslundsvägen 20B in... ► Artikel lesen | |
| 12.05. | New last trading day for paid subscription shares (BTA) of Magle Chemoswed Holding AB | 179 | GlobeNewswire | At the request of Magle Chemoswed Holding AB, the last trading day in Magle Chemoswed Holding AB's paid subscription shares will be changed from 2026-05-20 to 2026-05-13.
Instrument:
Paid subscription... ► Artikel lesen | |
| 30.04. | Magle Chemoswed Holding AB: Magle Group Announces Outcome of Rights Issue | 166 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 14.04. | Magle Chemoswed Holding AB: Magle Group Publishes Information Document in Connection with Upcoming Rights Issue | 195 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 13.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026 | 159 | Xetra Newsboard | Das Instrument LUR SE0015192075 LUXBRIGHT AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026 The instrument LUR SE0015192075 LUXBRIGHT AB EQUITY is traded ex capital adjustment on 13.04.2026Das... ► Artikel lesen | |
| 10.04. | Magle Chemoswed Holding AB: Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ) | 162 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), today, on 10 April 2026, held an Extraordinary General Meeting (the "EGM") at the Company's premises at Agneslundsvägen 20B in... ► Artikel lesen | |
| 27.03. | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2025 | 186 | GlobeNewswire (Europe) | Magle Group's Q4 report highlights restructuring measures, portfolio clean-up and a focus on improving profitability in a challenging financial environment.
Q4 2025 KEY INDICATORSNet Sales amounted... ► Artikel lesen | |
| 25.03. | Magle Chemoswed Holding AB: Magle Group's Board Of Directors Has Resolved On A Rights Issue Of Approx Sek 40 Million And Agreed A Revised Financing Package | 174 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 18.02. | Magle Chemoswed Holding AB: Magle Group Issues Profit Warning Ahead of Q4 and Full-Year 2025 Results | 173 | GlobeNewswire (Europe) | Magle Group today issues a profit warning in advance of the publication of its Q4 2025 Interim Report and Full-Year 2025 Results, now scheduled for release on March 27, 2026.
This follows the Group's... ► Artikel lesen | |
| 29.01. | Magle Chemoswed Holding AB: Magle Group Announces Strategic Refocus to Strengthen Profitability and Operational Discipline | 204 | GlobeNewswire (Europe) | Magle Group today announces a strategic direction focused on strengthening profitability, operational discipline, and long-term value creation. The Group will prioritise its most established revenue-generating... ► Artikel lesen | |
| 21.01. | Magle Chemoswed Holding AB: Magle Group Announces Planned Transition in Chief Operating Officer Role | 178 | GlobeNewswire (Europe) | Magle Group today announces that Fredrik Andersson, Chief Operating Officer, will step down from his position during the coming months, as part of a planned leadership transition. This decision has... ► Artikel lesen | |
| 01.12.25 | Magle Chemoswed Holding AB: Magle Group Enters Strategic Distribution Agreement with Rifa Pharma for SmartPAN and SmartGEL in India. | 199 | GlobeNewswire (Europe) | Magle Group is pleased to announce that it has entered into an exclusive distribution agreement with Rifa Pharma for the Indian market, covering both SmartPAN® and SmartGEL®.
This partnership represents... ► Artikel lesen | |
| 27.11.25 | Magle Chemoswed Holding AB: Magle Chemoswed Holding Announces Chairman Transition | 198 | GlobeNewswire (Europe) | As of today, Hans Henrik Lidgard steps down as Chairman of the Board for health reasons and will remain on the Board. In accordance with the procedural rules of the Board of the Company, Vice-Chairman... ► Artikel lesen | |
| 17.11.25 | Magle Chemoswed Holding AB: Magle Group Completes European Medical Device Filing for the Use of EmboCept S in Genicular Artery Embolisation | 341 | GlobeNewswire (Europe) | Magle Group today announces that it has successfully completed its European medical device filing to extend the clinical use of EmboCept® S, the company's proprietary degradable starch microsphere (DSM)... ► Artikel lesen | |
| 14.11.25 | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Third Quarter 2025 | 228 | GlobeNewswire (Europe) | Magle Group announces its Q3 2025 results, marked by clear progress across key areas of the business.
Q3 2025 KEY INDICATORSNet Sales amounted to 71.5 MSEK (64.6)EBITDA equaled 33.4 MSEK (26.5)Operating... ► Artikel lesen | |
| 22.10.25 | Magle Chemoswed Holding AB: Magle Biopolymers receives 2026 order showing a material increase in demand for one of its proprietary dextran derivatives | 283 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ) ("Magle Group") today announces that its subsidiary, Magle Biopolymers AB, has received an order for 2026 from a customer, representing a material increase in demand... ► Artikel lesen | |
| 20.10.25 | Magle Chemoswed Holding AB: Magle Group announces positive clinical evidence review of EmboCept S for Genicular Artery Embolisation (GAE); regulatory filing in Europe now in preparation | 255 | GlobeNewswire (Europe) | Magle Group today announces that its review of available clinical evidence for the use of EmboCept® S in Genicular Artery Embolisation (GAE) for symptomatic knee osteoarthritis demonstrates excellent... ► Artikel lesen | |
| 01.08.25 | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Second Quarter 2025 | 263 | GlobeNewswire (Europe) | Magle Group announces its Q2 2025 results amid short-term macroeconomic challenges, highlighting underlying strategic progress despite a temporary setback in financial performance. The quarter was impacted... ► Artikel lesen | |
| 29.07.25 | Magle Chemoswed Holding AB: Magle Group's financial results for the second quarter anticipated to fall short of market expectations. | 250 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ) ("Magle Group") today announces that the company's financial performance in the second quarter of 2025 is likely to fall short of market estimates. The deviation is... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 33,480 | -4,70 % | Märkte am Morgen: Delivery Hero, MTU, Lufthansa, TUI, Airbus, Bayer, Space X | Nach der außergewöhnlichen Feiertagskonstellation - Pfingstmontag mit Handel in Deutschland, Memorial Day ohne Handel in den USA - tritt der DAX heute leicht auf die Bremse (-0,3 % erwartet). Gestern... ► Artikel lesen | |
| MERCK KGAA | 130,75 | 0,00 % | DAX-Check LIVE: Delivery Hero, Infineon, Merck, Nordex, Secunet, Siemens im Fokus | Der deutsche Aktienmarkt hat den Pfingstmontag mit einem fulminanten Kurssprung begangen. Der DAX startete mit Gewinnen, übersprang direkt die wichtige Marke von 25.000 Punkten und kletterte im Verlauf... ► Artikel lesen | |
| NOVO NORDISK | 37,750 | -1,05 % | Novo Nordisk-Aktie: Droht jetzt ein Kurssturz um -30%? | Der jüngste Aufwärtstrend der Novo Nordisk-Aktie ging Mitte Mai zu Ende. Der Kurs des dänischen Pharmakonzerns schaffte es nicht mehr über die Hürde von 300 DKK. Und nun droht nach Einschätzung eines... ► Artikel lesen | |
| PFIZER | 22,020 | -0,07 % | BARCLAYS stuft PFIZER INC auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Pfizer mit einem Kursziel von 25 US-Dollar auf "Underweight" belassen. Angesichts der bisherigen Erfahrungen... ► Artikel lesen | |
| ELI LILLY | 929,40 | -0,10 % | HBM Healthcare Investments AG: Eli Lilly übernimmt HBM-Portfoliounternehmen Curevo für bis zu USD 1.5 Milliarden | HBM Healthcare Investments AG
/ Schlagwort(e): Ankauf
Eli Lilly übernimmt HBM-Portfoliounternehmen Curevo für bis zu USD 1.5 Milliarden
26.05.2026 / 13:10 CET/CEST
Die... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 81,47 | +0,56 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 28,680 | 0,00 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 375,95 | -0,27 % | Vertex: FDA Accepts BLA Submission For Povetacicept; Assigns PDUFA Target Action Date Of Nov. 30 | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has accepted its Biologics License Application submission for povetacicept, an investigational... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,970 | 0,00 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| NOVARTIS | 125,94 | +0,27 % | DEUTSCHE BANK RESEARCH stuft NOVARTIS AG auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis anlässlich der Investorenveranstaltung "dbAccess European Champions Conference" mit einem Kursziel von 135 Franken... ► Artikel lesen | |
| ABBOTT LABORATORIES | 75,46 | +0,05 % | EQS-News: Abbott erhält CE-Kennzeichnung für die weltweit erste duale Glukose-Keton-Sensortechnologie für Menschen mit Diabetes | EQS-News: Abbott
/ Schlagwort(e): Expansion/Sonstiges
Abbott erhält CE-Kennzeichnung für die weltweit erste duale Glukose-Keton-Sensortechnologie für Menschen mit Diabetes
27.05.2026... ► Artikel lesen | |
| ABBVIE | 183,30 | +0,11 % | AbbVie Announces European Commission Approval of AQUIPTA (atogepant) for the Acute Treatment of Migraine in Adults | AQUIPTA (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the prophylaxis of migraine in adults who have at least... ► Artikel lesen | |
| MERCK & CO | 98,68 | -0,35 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Aroundtown, Kingfisher sowie Merck & Co | © Foto: © 2023 Merck & CoGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:45... ► Artikel lesen | |
| GSK | 21,170 | -0,38 % | GSK erzielt teilweisen Therapieerfolg mit Hepatitis-B-Wirkstoff | DJ GSK erzielt teilweisen Therapieerfolg mit Hepatitis-B-Wirkstoff
Von Adria Calatayud
DOW JONES--GSK hat mit einem Medikamentenkandidaten gegen Hepatitis B einen teilweisen Therapieerfolg... ► Artikel lesen | |
| ZOETIS | 66,74 | +0,09 % | Argus downgrades Zoetis stock rating on competition, margin pressure |
MAGLE CHEMOSWED HOLDING AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +3,73 % bei einem Aktienkurs von 0,334 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAGLE CHEMOSWED HOLDING AB finden Sie auf Wallstreet Online.